Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: A systematic review

被引:25
作者
Amdal, Cecilie Delphin [1 ]
Jacobsen, Anne-Birgitte [1 ]
Guren, Marianne Gronlie [1 ]
Bjordal, Kristin [1 ]
机构
[1] Oslo Univ Hosp, Div Canc Med Surg & Transplantat, Dept Oncol, Oslo, Norway
关键词
QUALITY-OF-LIFE; PROTRACTED VENOUS-INFUSION; ADVANCED ESOPHAGOGASTRIC CANCER; RANDOMIZED PHASE-III; GASTROESOPHAGEAL JUNCTION; PLUS CISPLATIN; 1ST-LINE TREATMENT; STENT PLACEMENT; CLINICAL-TRIALS; BRACHYTHERAPY;
D O I
10.3109/0284186X.2012.731521
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Patient-reported outcomes (PROs) and assessments of treatment-related toxicity provide important information on the effect of palliative chemotherapy and/or radiotherapy. The aim of this study was to review the effect of palliative radiotherapy and/or chemotherapy on symptoms and quality of life assessed by PROs and measurement of toxicity for patients with oesophageal cancer. Methods. The Central, Medline and Embase databases (1990 to November 2011) were systematically searched for prospective studies of palliative chemotherapy and/or radiotherapy in patients with advanced oesophageal cancer with PRO- and/or toxicity outcomes. The risks of bias were assessed. Results. Of 2677 records identified, only 32 included PROs, of which eight were randomised controlled trials. In studies with sufficient standard of PRO (n = 18), either Health Related Quality of Life (HRQL) (n = 14) or patient-reported dysphagia (n = 4), were assessed. Docetaxel added to cisplatin + fluorouracil (CF) improved HRQL compared to CF only, even though toxicity increased. Epirubicin added to CF resulted in longer preserved HRQL than its comparator in two trials, and non-inferiority in one. All phase II chemotherapy studies reported maintained HRQL or improved dysphagia combined with low level of toxicity. Brachytherapy resulted in better HRQL compared to stent placement in two trials, and external radiotherapy relieved dysphagia. The quality of the HRQL methodology and the interpretation and presentation of the PRO results varied, and clinical significance was seldom discussed. Conclusion. PRO endpoints are seldom used and further studies of homogenous patient groups with valid measures and methodology of PROs should be encouraged in the evaluation of palliative treatment. Brachytherapy, external radiotherapy and combination chemotherapy improved HRQL and dysphagia in the few identified studies with sufficient PRO methodology.
引用
收藏
页码:679 / 690
页数:12
相关论文
共 53 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Characteristics and implications of attrition in health-related quality of life studies in palliative care [J].
Ahlner-Elmqvist, M. ;
Bjordal, K. ;
Jordhoy, M. S. ;
Kaasa, S. ;
Jannert, M. .
PALLIATIVE MEDICINE, 2009, 23 (05) :432-440
[3]   CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma - Results of a Phase II study [J].
Ajani, JA ;
Baker, J ;
Pisters, PWT ;
Ho, L ;
Mansfield, PF ;
Feig, BW ;
Charnsangavej, C .
CANCER, 2002, 94 (03) :641-646
[4]   Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 study group [J].
Ajani, Jaffer A. ;
Moiseyenko, Vladimir M. ;
Tjulandin, Sergei ;
Majlis, Alejandro ;
Constenla, Manuel ;
Boni, Corrado ;
Rodrigues, Adriano ;
Fodor, Miguel ;
Chao, Yee ;
Voznyi, Edouard ;
Awad, Lucile ;
Van Cutsem, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3210-3216
[5]  
Bamias A, 1996, CANCER, V77, P1978, DOI 10.1002/(SICI)1097-0142(19960515)77:10<1978::AID-CNCR3>3.0.CO
[6]  
2-D
[7]   Evidence-based radiation oncology: Oesophagus [J].
Berger, Bernhard ;
Belka, Claus .
RADIOTHERAPY AND ONCOLOGY, 2009, 92 (02) :276-290
[8]   Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial [J].
Bergquist, H ;
Wenger, U ;
Johnsson, E ;
Nyman, J ;
Ejnell, H ;
Hammerlid, E ;
Lundell, L ;
Ruth, M .
DISEASES OF THE ESOPHAGUS, 2005, 18 (03) :131-139
[9]   A prospective comparison of quality of life measures for patients with esophageal cancer [J].
Blazeby, JM ;
Kavadas, V ;
Vickery, CW ;
Greenwood, R ;
Berrisford, RG ;
Alderson, D .
QUALITY OF LIFE RESEARCH, 2005, 14 (02) :387-393
[10]   Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer [J].
Blazeby, JM ;
Nicklin, J ;
Brookes, ST ;
Winstone, K ;
Alderson, D .
BRITISH JOURNAL OF CANCER, 2003, 89 (03) :497-501